Human Papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Preventive Medicine (Impact Factor: 3.09). 12/2008; 48(5):426-31. DOI: 10.1016/j.ypmed.2008.11.010
Source: PubMed


To report awareness of human papillomavirus (HPV) and HPV vaccine among women aged 18-49 years and, for recommended women aged 18-26 years, estimate initiation of HPV vaccination and describe factors associated with vaccination initiation among a national sample.
Data were analyzed from the National Immunization Survey-Adult, a nationally representative telephone survey conducted May-August 2007. Questions were asked about awareness of HPV and HPV vaccine and vaccine receipt.
A total of 1102 women aged 18-49 years were interviewed, 168 were aged 18-26 years. Overall, awareness of HPV (84.3%) and of HPV vaccine (78.9%) were high. Among women 18-26 years of age, vaccination initiation (> or =1 dose) was 10%. Factors associated with vaccination included not being married, living > or =200% of the federal poverty index, having health insurance, and vaccination with hepatitis B vaccine. HPV vaccination initiation among women aged 27-49 years was 1%.
Awareness of HPV and HPV vaccine were high. Two to 5 months after national HPV vaccination recommendations were published, one in ten women 18-26 years old had initiated the HPV vaccine series. Women at a higher socio-economic level were more likely to receive the vaccination. Vaccination initiation and completion will likely increase over the next years. Monitoring uptake is important to identify sub-groups that may not be receiving the vaccination.

7 Reads
  • Source
    • "Previous studies on the knowledge of HPV infection and vaccines; and acceptability of HPV vaccines among health care providers and the public have shown varied results (Makwe CC 2011, Jain N 2009, Dursun P 2009, Christian WJ 2009, Klug SJ 2008, Riedesel JM 2005, Daley MF 2006, Songthap A 2009, Kwan TT 2009, Jones M 2008) (Tozzi AE 2009). Majority of these studies are however from developed countries. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Availability of effective vaccine against cervical cancer is not synonymous with effective control program. Awareness and knowledge of the vaccine is pertinent to its uptake. It is important to identify possible barriers to successful HPV vaccination program among young people. Materials and Methods A cross-sectional study of 572 female students selected by probability sampling technique from two Universities in South West, Nigeria was carried with the use of self-administered questionnaire. Results The proportion of respondents who were able to correctly identify risk factors for cervical cancer ranged from 14.3% (increasing age) to 53.5% (Chlamydia infection). Less than 50% of the participants were found to be knowledgeable about all the knowledge themes except the preventable nature of cervical cancer of which 62.9% were knowledgeable. The commonest sources of information were health care providers and seminars (44.1% each). Three hundred and forty-six (60.5%) respondents were willing to receive the vaccine. Age, faculty, age at menarche, awareness of HPV infection and cervical cancer; and all the knowledge themes except the need for male vaccination shows statistically significant relationship with acceptability of HPV vaccine (p < 0.05). Possible barrier to successful implementation of HPV vaccination program among young people in Nigeria were also identified. Inadequate information was thought to be the major barrier (68.9%). The other barriers were cost (38.1%), worry about possible complications (15.0%) and vaccine efficacy (13.3%); and lack of parental consent for vaccination (12.9%). Conclusion Knowledge of HPV vaccine is poor but its acceptability is high. Successful HPV vaccination program will depend on innovative and multi-pronged campaign that addresses various misconceptions about the vaccine. Economic accessibility of the vaccines also needs to be enhanced.
    Full-text · Article · Nov 2015 · International Journal of Advanced Research
  • Source
    • "d Calculated as the total number of annual cases attributed to HPV divided by the total number of anogenital cases per year. who had received one dose and were eligible to complete the series, 73.2% received all three doses [6] [7] [8] [9]. In Israel, private vaccination coverage rates remain low, at around 10% of eligible women. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Barriers to human papillomavirus (HPV) vaccine acceptability in Israel include Israel's relatively low incidence of cervical cancer; the religiously-based 80% circumcision rate in Israel, which is regarded as contributing to the lower incidence of HPV infection in the country; the fact that HPV vaccine provides immunity against only few virus types; the vaccine's high cost; and the perception that HPV transmission is associated with unacceptable sexual relations. A recent survey has demonstrated that, following media two campaigns, Israeli's level of awareness of the vaccine increased but the actual vaccination rate remained low, at approximately 10%. Survey findings also indicated that an enduring barrier to HPV vaccination is the vaccine's high cost. Recent research on a convenience sample of Israeli undergraduate women 21 to 24 years of age showed that intentions to receive HPV vaccination in the coming year were a function of women's attitudes towards getting vaccinated and their perceptions of social support for doing so. Undergraduate women who intended to be vaccinated perceived the prevention of cervical cancer, avoidance of personal health threat, and avoidance of HPV infection per se to be the advantages of undergoing HPV vaccination. Disadvantages of getting vaccinated included fear of vaccine side effects, cost of the vaccine, and newness of the vaccine, doubts about vaccines, time required to undergo multiple vaccinations, and dislike of injections. Friends', mothers' and physicians' recommendations influenced women's intentions to be vaccinated in the coming year as well. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in Israel" Vaccine Volume 31, Supplement 8, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
    Full-text · Article · Nov 2013 · Vaccine
  • Source
    • "knew about HPV vaccine. A previous study among women in the United states reported that the level of awareness of HPV and of HPV vaccine were 84.3% and 78.9% [17]. More comparable, a study among the rural folks in Penang Malaysia estimated that about 42.2% women ever heard about HPV vaccine [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Expanded Program on Immunization currently considers offering Human Papilomavirus vaccine on a routine basis in Vietnam. However, as the current available vaccine can prevent only two types HPV 16 and 18, before implementing a large-scale vaccine campaign we need information about the prevalence of infection with only HPV 16 and 18 in Viet Nam. This study was done in 5 large cities in Vietnam to estimate the prevalence of HPV 16 and/or 18 infections and to explore the distribution of other high risk types of HPV among married women in these provinces. The study employed a cross-sectional design with multistage sampling. The sample size included 4500 married women in two rounds (aged ranged from 18-69 years old, median age: 40 year old). Participant were randomly selected, interviewed and given gynaecological examinations. HPV infection status (by real-time PCR kit using TaqMan probe) and HPV genotyping test (by Reverse dot blot) were done for all participants. The prevalence of cervical infection with HPV type 16 and/or 18 among married women in this study ranged from 3.1% to 7.4%. Many positive HPV cases (ranged from 24.5% to 56.8%) were infected with other type of high risk HPV which can lead to cervical cancer and cannot prevented by currently available vaccines. In addition to HPV 16 and/or 18, most common types of high risk HPV were types 58, 52, 35 and 45. Awareness about HPV and HPV vaccines was still low in the study samples. While it is relevant to implement an HPV vaccine campaign in Viet Nam, it is important to note that one can be infected with multiple types of HPV. Vaccination does not protected against all type of high risk HPV types. Future vaccine campaigns should openly disclose this information to women receiving vaccines. High prevalence of infection with HPV high risk types was observed in this study. As HPV infection has a high correlation with cervical cancer, this study emphasizes the need for both primary prevention of cervical cancer with HPV vaccines as well as secondary prevention with screening.
    Full-text · Article · Feb 2013 · BMC Cancer
Show more